Publications database

In this issue: Naloxone, the overdose antidote that can help save lives | Tribute to outgoing Director Wolfgang Götz | New EMCDDA strategy and work programme | EU Member States’ common position...

The last decade has seen the emergence of new internet technologies that have acted as important facilitators of online drug markets. The internet now hosts a range of virtual marketplaces (both on...

The EMCDDA strategy and work programme for 2016–18 and the 2016 annual work programme is based on the EMCDDA’s vision to contribute to a more secure and a healthier Europe. A more...

This publication examines the case for distributing naloxone, an emergency medication, to people who inject opioids such as heroin and to others who might witness an opioid overdose. Through its capacity to...

Brief interventions are psychosocial techniques designed to help recipients recognise harmful patterns of substance use, and to motivate and support them to address that use. Studies suggest that brief interventions in an...

The EMCDDA receives stable funding under Commission budget line B3-441 of the general budget of the European Union. Each year, a preliminary draft budget is presented by the Centre's Director to the...

This publication looks at the co-occurrence of drug use problems and mental health disorders, taking in the theoretical background of psychiatric comorbidity, the tools for clinical diagnosis and the prevalence and clinical...

In this issue: Lisbon Addictions 2015 — conference round-up | Sponsored sessions at Lisbon Addictions 2015 | EMCDDA 20 years of monitoring conference | EMCDDA signs Memorandum of Understanding with Georgia |...

This publication presents the data and findings of the risk assessment on 4,4’-DMAR (4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine), carried out by the extended Scientific Committee of the EMCDDA on 16 September 2014. The main part of...

This publication presents the data and findings of the risk assessment on MT-45 (1-cyclohexyl-4-(1, 2-diphenylethyl)piperazine), carried out by the extended Scientific Committee of the EMCDDA on 16 September 2014. The main part...